AptaBio Therapeutics Inc. announced a private placement of series 1 unregistered non-guaranteed privately placed convertible bonds for a gross proceeds of KRW 38,900,000,000, and 1,037,574 registered convertible preferred shares at a price of KRW 10,698 per preferred share for gross proceeds of KRW 11,099,966,652; for aggregate gross proceeds of KRW 49,999,966,652 on August 16, 2023. The company is raising funding through third-party allotment rights issue for the preferred shares. The transaction has been approved by the board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,010 KRW | +0.17% | -2.91% | -33.59% |
1st Jan change | Capi. | |
---|---|---|
-33.59% | 97.85M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- A293780 Stock
- News AptaBio Therapeutics Inc.
- AptaBio Therapeutics Inc. announced that it expects to receive KRW 49.999966652 billion in funding